Insider trade

Viatris (VTRS): Director bought ~$2.2K

David S Simmons, Director at Viatris, bought ~$2.2K of Viatris shares.

~$2.2K
Approx. value · 213 sh @ $10.43
1,183
Holds after · shares reported
Traded
Nov 3, 2025
Filed
Mar 10, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 4, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 4, 2025, Viatris Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) to report the appointment of David Simmons to the Board of Directors of the Company (the “Board”).”
  2. Sep 11, 2025InsiderOfficer sold ~$72K of VTRS shares in the open market
  3. Oct 17, 20255% stakeBlackRock, Inc. reported a passive stake (13G) of 6.6%
  4. Oct 24, 2025Company filing · Form 8-K · Bylaws or charter, Shareholder Director NominationsChanged its bylaws, charter or fiscal year, and set the date for shareholder nominations (and 1 more item)
  5. Nov 3, 2025FDAFDA drug approval: Linagliptin

What came next

  1. Nov 6, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  2. Nov 10, 20255% stakeDAVIS SELECTED ADVISERS reported a passive stake (13G) of 6.7%
  3. Nov 18, 2025CongressDisclosed purchase of VTRS — reported range $1,001 - $15,000
  4. Dec 3, 2025FDAFDA drug approval: Macitentan
  5. Dec 12, 2025FDAFDA drug approval: Octreotide Acetate
  6. Jan 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 3, 2026, Viatris Inc. (the “Company”) announced that Brian Roman, Chief Legal Officer of the Company, would transition from his role with the Company and cease to serve as Chief Legal Officer effective as of February 9, 2026.”
  7. Feb 4, 20265% stakeDAVIS SELECTED ADVISERS reported a passive stake (13G) of 6.1%
  8. Feb 23, 2026Company filing · Form 8-K · Results, RestructuringAnnounced job cuts, closures or a restructuring, and reported its results (and 1 more item)“On February 26, 2026, the Company announced the results of its EWSR, and as a part of the review, committed to and began implementation of certain restructuring activities.”
  9. Feb 24, 2026FDARecall: Amnesteem (Isotretinoin) Capsules, USP 40 mg, packaged in 3 x 10-Count Prescription Packs, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, W…
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Viatris

For Viatris, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VTRS page.

Other recent filings by David S Simmons, Director

The full history of David S Simmons, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Viatris (VTRS) insider traded, and how much?

David S Simmons, Director at Viatris, bought ~$2.2K of Viatris shares. 213 shares at $10.43, open market.

When did it happen, and when was it made public?

Traded: Nov 3, 2025. Filed: Mar 10, 2026. That is 127 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Viatris recently?

For Viatris, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the VTRS page.

Does this mean VTRS stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Viatris

Everything OQRO holds on this company is on its VTRS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data